Impact of tirzepatide in a patient with type 1 diabetes and obesity: A case report

Letter Endocrinology & Metabolism

Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): A randomized double-blind placebo-controlled trial

Charles Thivolet et al.

DIABETES & METABOLISM (2023)

Add to Collection

Article Endocrinology & Metabolism

Glycemic Targets: Standards of Care in Diabetes-2023

Nuha A. ElSayed et al.

DIABETES CARE (2023)

Add to Collection

Article Endocrinology & Metabolism

Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes

Signe Schmidt et al.

Summary: Liraglutide treatment led to decreased fat and lean body mass, as well as reduced intake of added sugars, while no significant difference in total daily energy intake was observed between liraglutide- and placebo-treated participants.

DIABETES OBESITY & METABOLISM (2022)

Add to Collection

Article Endocrinology & Metabolism

Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes

Valentina Pirro et al.

Summary: Tirzepatide significantly reduced HbA1c and body weight in subjects with type 2 diabetes compared to dulaglutide, modulating metabolites associated with insulin resistance, obesity, and future T2D risk. These metabolic changes were proportional to improvements in glycemic control and beta-cell function, indicating a unique effect of tirzepatide on metabolic health.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Add to Collection

Article Endocrinology & Metabolism

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

Tim Heise et al.

Summary: Tirzepatide demonstrates remarkable glucose-lowering ability in patients with type 2 diabetes by improving insulin secretion and sensitivity. Compared to other GLP-1 receptor agonists, Tirzepatide shows more significant improvements in glucose metabolism.

LANCET DIABETES & ENDOCRINOLOGY (2022)

Add to Collection

Editorial Material Endocrinology & Metabolism

What's preventing us from curbing the obesity crisis?

[Anonymous]

LANCET DIABETES & ENDOCRINOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Tirzepatide Once Weekly for the Treatment of Obesity

Ania M. Jastreboff et al.

Summary: In this 72-week trial in participants with obesity, once-weekly doses of 5 mg, 10 mg, or 15 mg of tirzepatide provided substantial and sustained reductions in body weight, and improvements in cardiometabolic measures were also observed.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Endocrinology & Metabolism

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

Melissa K. Thomas et al.

Summary: Tirzepatide demonstrated significantly greater improvements in insulin sensitivity and beta-cell function compared to dulaglutide, with only partial contributions from weight loss. The dual receptor agonism of tirzepatide may confer distinct mechanisms of glycemic control beyond just weight reduction.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Julio Rosenstock et al.

Summary: Tirzepatide demonstrated significant improvements in glycemic control and body weight without increasing the risk of hypoglycemia. The safety profile was consistent with GLP-1 receptor agonists, suggesting a potential monotherapy use for the treatment of type 2 diabetes.

LANCET (2021)

Add to Collection

Article Endocrinology & Metabolism